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Background: The suppressed production of nitric oxide 
(NO), associated with endothelial dysfunction, is 
thought to be a cause of ischemia and reperfusion injury 
of the liver. But findings of the salutary effects of NO 
enhancement on such injury have been conflicting. In 
this study, we tested our hypothesis that NO enhance-
ment would attenuate ischemic liver injury. For this pur-
pose, an NO precursor, L-arginine, and a novel NO 
donor, FK409, were applied to a 2-hour total hepatic 
vascular exclusion model in dogs. 
Study Design: L-arginine was administered IV at a dose 
of 100 mglkg twice (n = 5), while 300 mg/kg twice of 
FK409 was infused continuously into the portal vein 
(n = 5). The drugs were given to the animals for 30 and 
60 minutes before and after ischemia, respectively. Non-
treated animals were used as the control (n = 10). Two-
week survival, systemic and hepatic hemodynamics in-
dices, liver function tests, energy metabolism, and 
histopathology were analyzed. 
Results: Both treatments comparably augmented he-
patic tissue blood flow, decreased liver enzyme release, 
and increased high-energy phosphate restoration during 
the reperfusion period, all of which contributed to res-
cuing all of the treated animals from the 2-hour total 
hepatic ischemia. In contrast, ischemia caused 70% 
mortality in the control group. Histologically, structural 
abnormality and neutrophil infiltration were markedly 
attenuated by the treatments. Systemic hypotension was 
observed in the animals treated with FK409, however. 
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Conclusions: Our data demonstrate that NO enhance-
ment alleviates the liver injury caused by ischemia and 
reperfusion. The supplementation of L-arginine, rather 
than FK409, is considered more applicable to clinical 
use because of the absence of systemic adverse effects. (J 
Am Coll Surg 1999;188:43-52. © 1999 by the Amer-
ican College of Surgeons) V 
Vasoconstriction or microcirculatory disturbance in-
duced by superoxide-mediated endothelial cell dys-
function has been considered one of major causes of 
liver injury associated with ischemia and subsequent 
reperfusion. Preischemic or postischemic adminis-
tration of antioxidants, prostanoid-modulating 
drugs, adenosine-regulating agents, and antiendo-
thelin antibody, all of which act as vasodilators, has 
been shown to attenuate postischemic hepatic 
damage. 1-3 Nitric oxide (NO), an endothelium-
derived relaxing factor with various beneficial bio-
logic actions, is another therapeutic candidate that 
may protect the liver against the noxious insult. Find-
ings of the salutary effects of NO on ischemia and 
reperfusion injury of the liver have been conflicting, 
however. Ma and associates4 demonstrated detrimen-
tal results with NO augmentation, but Jaeschke and 
colleagues5 and Wang and coworkers6 observed no 
important improvements by the treatment. Al-
though Shiraishi and colleagues7 and Koeppel and 
associates8 described beneficial properties of NO, 
their observations were confined to the effects on 
hepatic blood flow or liver enzyme release. 
In the present study, we tested our hypothesis 
that NO enhancement would attenuate vascular dys-
function, lessen neutrophil-related tissue injury, and 
reduce ischemia and reperfusion injury of the liver. 
For this purpose, we tested an NO precursor, 
L-arginine, and a novel NO donor, FK409,9 in dogs 
subjected to 2-hour total hepatic vascular exclusion. 
Therapeutic effects of the agents were determined by 
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the animals' 2-week survival, the severity of liver in-
jury, and hepatic and systemic hemodynamic 
indices. 
METHODS 
The study was conducted with the approval of the 
Institutional Animal Care and Use Committee of 
Hokkaido University and the University of Pitts-
burgh, and was managed according to guidelines is-
sued by the National Institutes of Health and the 
Public Health Service Policy on the humane use and 
care of laboratory animals. 
Animals 
After overnight fasting, adult female beagle dogs, 
weighing 8.0 to 12.0 kg, were anesthetized with an 
IV injection of thiopental sodium (Abbott Laborato-
ries, North Chicago, IL), 25 mg/kg. They were then 
intubated, and anesthesia was maintained by positive 
mechanical ventilation with a gas mixture of isoflu-
rane (1.0%), nitrous oxide (2 Llmin), and oxygen (2 
Llmin). The right carotid artery and the right jugular 
vein were cannulated for monitoring arterial and 
central venous pressures. ECGs and esophageal tem-
perature were monitored during the operation. An 
electrolyte solution (Plasmalyte; Baxter, Deerfield, 
IL) was infused continuously into the animals at a 
rate of 20 mLlkg/h throughout the procedure. Arte-
rial blood gas and electrolytes levels were measured 
frequently and corrected if necessary by administra-
tion of sodium bicarbonate, calcium dichloride, and 
potassium chloride. 
Operative Procedures 
After midline laparotomy, the liver was completely 
skeletonized by dissecting all of the suspensory liga-
ments and the retrohepatic vena cava from the pos-
terior abdominal wall. 1 During the total hepatic vas-
cular exclusion, we used venovenous bypass to 
decompress the splanchnic venous beds and the in-
frahepatic IVe. The system was equipped with the 
centrifugal pump (Biomedicus 520D, Minetonka, 
MN) and Tygon tubings (Norton Industrial Plastics, 
Akron, OH) connecting the left femoral and the 
splenic and left jugular veins. The bypass flow was 
maintained at more than 50 mLlkg/min. Heparin 
sodium (Upjohn, Kalamazoo, MI), 50 U/kg, was ad-
ministered IV 5 minutes before ischemia. Total he-
patic vascular exclusion was achieved by cross-
clamping the portal vein, the hepatic artery, and the 
IVC both above and below the liver. The exclusion 
was continued for 2 hours, and then the liver was 
reperfused by removing the clamps. Immediatelyaf-
ter reperfusion, the bypass system was disconnected 
. and a splenectomy was performed. The animals were 
allowed to eat and drink the morning after the oper-
ation and were observed for 2 weeks. Cefamandole 
nafate, 1 g, was given intraoperatively, and adminis-
tration was continued for 3 days postoperatively. 
Experimental Groups 
Twenty dogs were randomly divided into three 
groups: group CT (n = 10), untreated control; 
group LA (n = 5), treated with L-arginine; and 
group FK (n = 5), treated with FK409. L-arginine 
(Sigma Chemical Co., St. Louis, MO) was dissolved 
in physiologic saline at a concentration of 50 mgl 
mL. The novel NO donor, FK409 (Fujisawa Phar-
maceutical Co., Osaka, Japan), was also dissolved in 
physiologic saline at a concentration of 150 /Lg/mL. 
In group LA, L-arginine at a dose of 100 mg/kg was 
administered IV for 30 minutes before ischemia and 
for 60 minutes after ischemia, starting 5 minutes 
before reperfusion. In group FK, FK409 at a dose of 
300 /Lg/kg was given continuously into the portal 
vein through a branch of the mesenteric veins for 30 
minutes before ischemia and for 60 minutes after 
ischemia, beginning 5 minutes before reperfusion. 
Determinations 
The cytoprotective effects of the drugs were assessed 
by the following measures: 2-week animal survival, 
hepatic tissue blood flow (HTBF), liver enzyme re-
lease, serum total bile acid (TBA) and hyaluronic 
acid (HA) levels, tissue high-energy phosphate levels, 
and histopathologic findings. The influence of the 
drugs on systemic hemodynamic indices was evalu-
ated by the mean arterial blood pressure (MAP), 
which was calculated according to the following 
equation: 
MAP = diastolic arterial pressure 
+ (systolic arterial pressure 
- diastolic arterial pressure) X 1/3. 
The completeness of total hepatic vascular exclusion 
was confirmed by the indocyanine green (lCG) dye 
retention rate during ischemia. Briefly, ICG (Cardio-
Green; Becton Dickinson Microbiology Systems, 
Cockeysville, MD) at a dose of 0.5 mg/kg was given 
IV 30 minutes after the onset of vascular exclusion, 
and 3 mL of heparinized arterial blood was collected 
20 minutes after dye injection. The ICG retention 
rate was determined with the use of a spectropho-
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tometer (Lambda; Perkin Elmer, Norwalk, CT) at a 
wavelength of 805 nm. 
Hepatic tissue blood flow. HTBF was measured 
with use of a laser-Doppler flowmeter (Advance La-
ser Flowmeter, ALF21; Advance Company Ltd., To-
kyo, Japan) before ischemia; 5, 30, 60, 90, and 120 
minutes after ischemia; and 5, 15, 30, and 60 min-
utes after reperfusion. The measurements were re-
peated three times at three different lobes a~ each 
time point. The mean value of the measurements at 
respective time points was calculated and expressed 
as a percentage of the preischemic initial value. To 
avoid a misreading of HTBF measurements related 
to respiratory motion, we temporarily stopped the 
ventilator during the measurements. 
Liver enzymes. Blood samples for assessment of 
the release of liver enzymes were collected serially 
before ischemia; just before reperfusion and at 5, 15, 
30, and 60 minutes after reperfusion; 3, 6, 12, and 24 
hours after reperfusion; and on postoperative days 2, 
3,5,7,10, and 14. A Technicon RA500 autoanalyzer 
(Bayer, Tarrytown, NY) was used to determine serum 
levels of aspartate aminotransferase (AST), alanine 
aminotransferase, and LDH. 
Total bile acid and hyaluronic acid. The blood 
samples for TBA and HA measurements were col-
lected before ischemia, just before reperfusion, and 1, 
3,6, 12, and 24 hours after reperfusion. The serum 
TBA level was measured by the enzymatic fluorimet-
ric method with the Sterongnost-alpha Flu Kit (Nye-
gaad, Oslo, Norway).10 The serum HA level was de-
termined by the sandwich-binding protein assay of 
Chichibu and colleagues. II 
High-energy phosphates. Wedge liver biopsies 
were performed before ischemia, at the end of isch-
emia, and 15 and 60 minutes after reperfusion. Half 
of the specimen was immediately stored in liquid 
nitrogen for tissue biochemistry analysis, and the rest 
was ftxed with buffered formalin for histopathologic 
analysis. Tissue levels of the adenine nucleotides ATP, 
ADP, and AMP were determined with a Waters high-
performance liquid chromatography system (Model 
510 pumps, Model 484 absorbance module, and 
Model 717 WISP system; Waters Chromatography 
Division, Millipore Corp., Milford, MA) at 254 nm 
(Waters Model 484, a tunable absorbance detec-
tor).12 Total adenine nucleotide (TAN) and energy 
charge (EC) were calculated with the following equa-
tions, respectivelyl3: 
TAN = ATP + ADP + AMP 
and 
EC = (ATP + ADP X 1I2)/TAN. 
Histopathology. Formalin-fixed specimens were 
embedded in paraffin and stained with hematoxylin 
and eosin. Histopathologic analysis was performed 
by a single pathologist without knowledge of the 
groups or the timing of the tissue sampling. His-
topathologic damage was assessed semiquantitatively 
based on the degree of sinusoidal congestion, sinu-
soidal cell derangement, hepatocyte injury, and he-
patocyte necrosis, with each index scored as 
none = 0; mild = 1; moderate = 2; and se-
vere = 3. The number ofinftltrated polymorphonu-
clear cells (PMNs) per 1,000 hepatocyte nuclei was 
counted by observing the tissues stained by Leder's 
method. 14 
Statistical Analysis 
The data for continuous measurements were ex-
pressed as mean ± SEM in each of the three study 
groups of dogs. The animals' survival rates were com-
pared pairwise by Fisher's exact probability test. In-
tergroup analysis was performed using one-way 
ANOVA. When ANOVA showed a significant dif-
ference (p < 0.05), a post hoc test was used to deter-
mine the p values for each group. A two-sided p value 
< 0.05 was considered statistically signiftcant. These 
procedures were performed with the statistical pro-
gram StatView (version 4.5; Abacus Concepts, Inc., 
Berkeley, CA) on a Macintosh computer (Apple 
Computer, Inc., Cupertino, CA). 
RESULTS 
General Conditions 
Clinically, no bleeding tendency was observed in ei-
ther the control or the treated animals through-
out the procedure. The ICG retention rate was 
94.82% ± 1.26%, 95.05% ± 1.33%, and 96.24% ± 
1.15% in groups CT, LA, and FK, respectively, indi-
cating the completeness of the total hepatic vascular 
exclusion. 
Systemic Hemodynamics 
Mean arterial pressures in groups CT and LA re-
mained stable before ischemia. In contrast, remark-
able hypotension developed in the animals treated 
with FK409, reaching the nadir within 10 minutes 
after the initiation of drug infusion (Fig. 1). After the 
completion of preischemic FK409 administration, 
the blood pressure recovered rapidly and remained at 
a level similar to those in other two groups during the 
ischemic period. After reperfusion, serious hypoten-
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Figure 1. Changes in mean arterial pressure as an indicator of 
systemic hemodynamics. Mean arterial pressure was calculated ac-
cording to the following equation: MAP = diastolic arterial 
pressure + (systolic arterial pressure - diastolic arterial pres-
sure) X 1/3. Group CT, untreated control (n = 10); group LA, 
treated with L-arginine (n = ;); group FK, treated with FK409 
(n = ;). *p < 0.05 versus group CT; #p < 0.0; versus group LA. 
sion developed in all animals. Although the blood 
pressure was gradually elevated in group LA thereaf-
ter, significant hypotension was seen in groups CT 
and FK. Postreperfusion hypotension of group FK 
animals continued until the cessation of drug 
administration. 
Hepatic Tissue Blood Flow 
The changes ofHTBF in each group are illustrated in 
Figure 2. The preischemic drug administration in-
duced no remarkable changes in HTBF, representing 
approximately 100% of the initial value. Despite the 
complete ischemia, we noted false-positive tissue 
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Figure 3. Changes in serum aspartate aminotransferase (AST) level 
after reperfusion. Group CT, untreated control (n = 10); group 
LA, treated with L-arginine (n = ;); group FK, treated with 
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Figure 2. Changes in hepatic tissue blood flow (HTBF). Values are 
expressed as a percentage of the respective preischemic initial flow. 
Group CT, untreated control (n = to); group LA, treated with 
L-arginine (n = ;); group FK, treated with FK409 (n = ;). 
*p < 0.0; versus group CT. 
blood flow ranging from 8% to 11 %, which was due 
to limitations of the Doppler flow measurement 
technique. Immediately after reperfusion, all livers in 
group CT developed outflow block, characterized by 
conspicuous swelling, mottled reperfusion, and hard 
consistency. The HTBF of group CT animals was 
approximately 25% of the initial value throughout 
the observation. In contrast, all livers treated with 
L-arginine or FK409 demonstrated smooth and fast 
revascularization, with HTBF in the range of55% to 
60%. The HTBF levels in groups LA and FK were 
two to three times higher than that in group CT 
throughout the reperfusion period. 
Animal Survival 
The 2-hour warm ischemia of the liver was poorly 
tolerated by group CT animals, in which 7 of the 10 
dogs died ofliver failure; 6 died within 24 hours after 
reperfusion and 1 on the second postoperative day. In 
contrast, all of the animals treated with L-arginine or 
FK409 survived for 2 weeks. The 2-week survival 
rates of groups CT, LA, and FK were 30%, 100%, 
and 100%, respectively (group LA versus group CT, 
and group FK versus group CT, p < 0.05 for each 
comparison). 
Liver Function Tests 
Serum AST levels in control animals rose rapidly 
after reperfusion, reaching a peak value of 
11,521 ± 1,014 U/Lat 12hours;peakASTlevelsin 
groups LA and FK were 3,593 ± 1,260 and 
3,574 ± 1,154 U/L, respectively (Fig. 3). Compared 
with the control group, AST levels in the treated 
groups were significantly lower from 3 hours after 
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Table 1. Alanine Aminotransferase, Lactate Dehydrogenase, Total Bile Acid, 
and Hyaluronic Acid Levels After Reperfusion 
Measurement Before End of 
After reperfusion 
and group ischemia ischemia 1 h 3h 6h 12h 24h 
ALT 
CT 32 ± 4 33 ± 3 4,961 ± 798 6,576 ± 1,007 9,332 ± 1,128 13,563 ± 1,379 12,680 ± 1,451 
LA 17 ± 3 21 ± 2 1,610 ± 373* 2,277 ± 503* 2,732 ± 601* 3,214 ± 661 * 2,378 ± 517* 
FK 19 ± 6 26 ± 15 2,202 ± 758* 2,814 ± 1139* 3,766 ± 1,568* 3,410 ± 1,521* 2,789 ± 1,388* 
LDH 
CT 81 ± 16 173 ± 27 3,385 ± 474 3,128 ± 479 2,906 ± 559 3,046 ± 634 1,441 ± 216 
LA 72 ± 12 185 ± 52 1,391 ± 355* 1,250 ± 304* 968 ± 254* 693 ± 186* 261 ± 49* 
FK 121 ± 57 165 ± 99 1,991 ± 704 1,628 ± 623* 1,142 ± 314* 603 ± 192* 343 ± 128* 
TBA 
CT 0.3 ± 0.3 29.9 ± 6.3 48.5 ± 11.7 100.2 ± 11.0 133.8 ± 11.8 124.3 ± 13.1 175.4 ± 39.0 
LA 70.6 ± 19.4 87.6 ± 25.1 58.0 ± 35.2* 41.2 ± 22.4* 20.2 ± 6.7* 
FK 49.6 ± 10.8 83.6 ± 23.2 68.8 ± 24.4* 53.2 ± 13.4* 53.4 ± 24.5* 
HA 
CT 16.7 ± 6.5 348.9 ± 68.1 78.1 ± 27.5 61.4 ± 17.4 82.4 ± 30.9 112.6 ± 23.8 515.3 ± 167.5 
LA 9.4 ± 4.3 371.2 ± 113.5 28.8 ± 6.5 42.3 ± 22.7 39.4 ± 13.6 36.2 ± 10.3* 20Ll ± 50.0 
FK 12.2 ± 7.5 261.0 ± 84.8 22.8 ± 13.1 74.0 ± 33.2 55.9 ± 26.8 47.1 ± 13.4* 188.4 ± 60.2* 
ALT, alanine aminotransferase; cr, untreated control (n = 10); FK, group treated with FK409 (n = 5); HA, hyaluronic acid; LA, group treated with L-arginine 
(n = 5); LDH, lactate dehydrogenase; TBA, total bile acid. 
'p < 0.05 versus group cr. Data arc expressed as mean :!: SEM. 
reperfusion until postoperative day 3. No substantial 
difference was found in AST levels between the 
treated groups. Serum levels of alanine aminotrans-
ferase changed similarly to those of AST (Table 1). 
Serum LDH levels reached the peak value within 15 
minutes after reperfusion and slowly declined there-
after. The elevation of LDH was markedly sup-
pressed in groups LA and FK compared with group 
CT (Table 1). 
Total Bile Acid and Hyaluronic Acid Levels 
Serum HA levels exhibited two-phase changes, char-
acterized by peaks at the end of ischemia and at 24 
hours after reperfusion. Repeat elevation ofHA levels 
during the reperfusion period was significantly sup-
pressed in groups LA and FK compared with group 
CT (Table 1). 
Serum TBA levels rose similarly in all groups un-
til 3 hours after reperfusion (Table 1). The level in 
group CT animals rose progressively thereafter, but 
those of groups LA and FK animals gradually re-
verted to preoperative levels. 
Energy Metabolism 
Changes in the tissue levels of adenine nucleotides 
are summarized in Table 2. Two hours of total hepatic 
vascular exclusion induced significant decreases in 
tissue ATP and ADP levels, with a concomitant rise 
of AMP and decrease in TAN. AMP and TAN in 
groups LA and FK remained at significantly higher 
levels than those in the control group at the end of 
ischemia, howeVer, suggesting the delayed decay of 
adenine nucleotides to purine catabolites during the 
ischemic period. Although high-energy phosphates 
were restored rather quickly in all groups after reper-
fusion, resynthesis of ATP, ADP, and TAN was more 
rapid and significant in the animals treated with 
L-arginine and FK409 than in those in the control 
group. The energy charge showed no significant dif-
ferences at any time point among the groups. 
Histopathology 
Treatment with L-arginine or FK409 induced no ev-
ident histopathologic differences between the treated 
groups and the control group at the end of ischemia 
or 15 minutes after reperfusion. At 60 minutes after 
reperfusion, however, control livers were character-
ized by sinusoidal congestion, sinusoidal cell de-
rangement, ischemic hepatocyte changes, and hepa-
tocyte necrosis, all of which were significantly 
attenuated by the treatments (Fig. 4). In particular, 
the degrees of hepatocyte necrosis and ischemic he-
patocyte changes were remarkably lessened in the 
treated groups (Fig. SA). 
At the end of ischemia, no substantial changes 
were found in the number of infIltrated PMNs 
among the three groups. The PMN number in the 
control animals gradually and markedly increased af-
ter reperfusion, but the increases were significantly 
suppressed in groups LA and FK (Fig. SB). No sig-
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Table 2. Tissue Concentrations of Adenine Nucleotides (nmol/g Tissue) During Ischemia and After Reperfusion 
Energy 
Examination time ATP ADP ... AMP TAN charge 
Before ischemia 
CT 2,666.2 ± 310.6 894.0 ± 11.2 213.6 ± 29.0 3,773.7 ± 314.1 0.82 ± 0.02 
End of ischemia 
CT 236.9 ± 45.2 335.0 ± 29.1 1,147.1 ± 107.2 1,71S.9 ± 147.8 0.23 ±0.03 
LA 452.1 ± 187.3 665.0 ± 236.0 1,889.1 ± 185.9* 2,925.7 ± 560".7* 0.23 ± 0.04 
FK 338.9 ± 104.7 491.1 ± 141.9 1,706.6 ± 53.0* 2,536.8 ± 221.0 0.20 ± 0.05 
15 min after reperfusion 
CT 846.S ± 170.2 . 409.9 ± 65.6 160.0 ± 17.8 1,416.8 ± 234.0 0.72 ± 0.04 
LA 2,071.8 ± 338.6* 738.3 ± 146.7 276.4 ± 55.2 3,OS6.5 ± 365.8* 0.78 ± 0.04 
FK 2,041.2 ± 593.3* 866.0 ± 170.5* 431.8 ± 121.5* 3,339.2 ± 424.5* 0.74 ± O.OS 
60 min after reperfusion 
CT 1,227.2 ± 13S.3 329.4 ± 33.4 112.2 ± 14.7 1,66S.S ± 160.1 0.83 ± 0.02 
LA 2,181.4 ± 504.1 768.1 ± 94.5* 205.6 ± 47.7* 3,155.1 ± 527.1* 0.80 ± 0.04 
FK 2,314.6 ± 401.5* 774.6 ± 105.8* 274.2 ± 24.5* 3,363.4 ± 440.8* 0.78 ± 0.02 
*p < 0.05 versus f'0UP cr. Data arc expressed as mean ± SEM. . 
ADp, adenosine dlphosph~te; AM~ a.denosine monophosphate; ATP. adenosi~e triphosphate; cr. untreated control (n = 10); FK. group treated with FK409 
(n = 5); LA. group treated WIth L-argInine (n = 5), TAN. total adenIne nucleotldes. 
nificant differences were seen in the number of infil-
trated PMNs between the treated groups (Fig. 5B). 
DISCUSSION 
This study showed that hepatic warm ischemia for 2 
hours caused severe liver injury after reperfusion, re-
sulting in a 70% mortality rate for control animals. 
In contrast, enhancement of NO by L-arginine and a 
novel NO donor, FK409, exhibited a remarkable al-
leviating effect on such injury. Pre- and postischemic 
administration of these agents allowed 100% sur-
vival of the animals, augmented HTBF, enhanced 
bile acid metabolism, and lessened hepatocyte dam-
age. In addition, the treatments prevented the decay 
of high-energy phosphates during ischemia and ac-
celerated ATP restoration after reperfusion. His-
topathologic alterations were markedly attenuated 
by the treatments, with less PMN infiltration into 
postischemic liver tissues. 
NO is synthesized from NO synthases (NOS) 
through the L-arginine to L-citrulline pathway.15 
NOS are classified into two different types: calcium-
dependent constitutive NOS and calcium-
independent inducible NOS.16 Constitutive NOS 
are located in vascular endothelial cells and produce 
an appropriate amount of NO in response to circu-
latory environments,17 but inducible NOS synthe-
size NO excessively when stimulated by certain cyto-
kines or endotoxin. 18 NO has various biologic 
actions such as vasodilation (vascular smooth muscle 
relaxation) and inhibition of platelet aggregation; a 
mechanism for both involves the elevation of cyclic 
guanosine m~:nophosphate following soluble guany-
late cyclase activation by NO. 19•20 NO also has inhib-
itory effects on the endothelium-neutrophil interac-
tion, partially through down-regulation of the 
expression of adhesion molecules both on endothe-
lium and neutrophils21 •22 and of the production of 
cytokines by inflammatory cells.23 In the liver, NO 
has been reported to exert hepatic sinusoidal dilation 
and to improve the microcirculation of this organ by 
altering the morphofunctional activity of fat-storing 
(Ito) cells.24 
Our hypothesis in this study was based upon ev-
idence that a decrease of NO production by injured 
endothelial cells through the attack of reactive oxy-
gen species eliminate is one of the important mech-
anisms responsible for organ injury caused by isch-
emia and reperfusion.25 We experimented with 
elevation of the NO level by using the NO precursor 
L":arginine and a novel NO donor, FK409. To our 
knowledge, this is the first report to demonstrate not 
only that NO enhancement reduced ischemia and 
reperfusion injury of the liver, but also that treatment 
with L-arginine and FK409 rescued all dogs from the 
grave ischemic insult that caused 70% mortality in 
control animals. 
Shiraishi and associates7 also demonstrated that 
portal injection of L-arginine at a dose of 10 mg/kg 
induced a temporal burst of intrahepatic NO after 
reperfusion and mitigated the injury of rat and por-
cine livers subjected to 1 hour of ischemia followed 
by reperfusion. On the other hand, by using an iso-
lated rat liver perfusion model, Ma and colleagues4 
found that the inhibition of NO production by NW_ 
nitro-L-arginine methyl ester hydrochloride (L-
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Figure 4. Histologic examination of liver tissue 60 minutes after reperfusion (hematoxylin and eosin. X25). (A) 
Untreated control liver. Although basic architecture was preserved. severe sinusoidal congestion. mild sinusoidal cell 
derangement. and mild hepatocyte injury and necrosis were found. (B) The liver treated with FK409. Although mild 
sinusoidal congestion and sinusoidal cell derangement were recognized. neither hepatocyte injury nor necrosis was 
found. (C) The liver treated with L-arginine. Mild sinusoidal cell derangement was found. but sinusoidal congestion and 
hepatocyte inj,ury and necrosis were not observed. . . 
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Figure 5. (A) Histologic damage score. Histologic damage was assessed serruquantitatively based on the extent of 
sinusoidal congestion, sinusoidal derangement, hepatocyte injury, and hepatocyte necrosis. Each index was scored as 
none = 0; mild = 1; moderate = 2; and severe = 3. (B) Number of infiltrated polymorphonuclear cells (PMNs) in 
liver tissue. Data are expressed as mean =: SEM per 1,000 hepatocyte nuclei. Group CT, untreated control (n = 10); 
group LA, treated with L-arginine (n = 5); group FK, treated with FK409 (n = 5). *p < 0.05 versus group CT. 
NAME) attenuated liver injury after ischemia. Alter-
natively, Jaeschke and coworkers5 observed no 
substantial effects ofL-NAME treatment on rat liver 
ischemic injury. Although the conflicting results be-
tween our study and the others might be due to dif-
ferences in animal species, models, and agents tested, 
the data from our preclinical study in dogs reveal the 
manifest protective effects of NO against ischemia 
and reperfusion injury in the liver. 
Although the NO level was not determined di-
rectly in this study, we believe that L-arginine admin-
istration augmented NO production in sinusoidal 
endothelial cells. Mammalian vascular endothelial 
cells produce NO, L-citrulline, and water from 
L-arginine and oxygen as substrates through the par-
ticipation of NOS. Little information has been avail-
able as to the quantity of NO production by the cells 
after exogenous L-arginine administration under 
normal conditions.26.27 It has been proved, however, 
that once the cells are injured, they take up 
L-arginine preferentiallf8 and produce NO depend-
ing on L-arginine availability.29 Kakumitsu and asso-
ciatesl° reponed that exogenous L-arginine (30 
g/body) selectively decreased the sinusoidal resis-
tance and augmented the hepatopetal portal flow in 
cirrhotic patients who had deteriorated sinusoidal 
cells compared with healthy subjects, who also dem-
onstrated increased urinary excretion of an NO me-
tabolite, nitrate. Huk and coauthors31 demonstrated 
that the administration of L-arginine maintained 
NO production during reperfusion in a rabbit skel-
(. 
etal muscle.ischemia model. In addition, the enan-
tiomer of L-arginine (D-arginine), which has the 
same effect on humoral factors such as insulin and 
glucagon,'2 has been reported to have no effects on 
ischemia and reperfusion injury.33 These facts suggest 
that L-arginine administration in our study exened 
its effects through enhanced NO production in the 
injured sinusoidal endothelial cells rather than 
through humoral effects. On the other hand, NO 
enhancement by FK409 administration is evident 
because the agent spontaneously releases NO in the 
blood at a linear ratio of 1: 1 between its degradation 
and NO formation. 
FK409 is a novel semisynthetic product of Strep-
tomyces griseosporeus that acts as an NO donor, char-
acterized by the rapid release ofN 0 with a half-life of 
6 minutes in canine blood.9.34.35 Both L-arginine and 
FK409 provided similar and comparable hepatopro-
tective effects in our model; however, these agents 
had different influences on systemic hemodynamic 
indices. i~arginine administration caused minimal 
systemic hemodynamic changes which was consis-
tent with previous reports.26.36 In contrast, FK409 
caused transient but significant hypotension limited 
to the drug infusion period, even though this agent 
was given through the ponal vein. Although the ex-
act mechanism remains unclear, this phenomenon 
might be attributable to differences in the magnitude 
of NO production and in the organ specificity be-
tween the agents because the injured sinusoidal en-
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dothelial cells are thought to take up L-arginine and 
to produce NO eliminate. 
Mechanisms by which NO provided hepatopro-
tective effects against ischemia and reperfusion in-
jury were not fully determined in our study, but sev-
eral possibilities can be considered. First, it could be 
due to amelioration of the microcirculatory distur-
bance by the vasodilatory effect of NO. In this study, 
the treatments with L-arginine or FK409 restored 
postischemic HTBF to two- to three fold that of the 
control group. NO has been proved to regulate he-
patic sinusoidal circulation through morphofunc-
tional influences on Ito cells/4 rather than through a 
direct effect on portal or arterial vascular smooth 
muscle cells. Feletou and coworkers37 showed that 
the canine portal mesenteric veins were insensitive to 
NO stimulation. Because NO has been shown to 
modulate other vasoactive substances such as endo-
thelin38 and prostanoids,39 NO-driven changes of 
these vasoactive substances might contribute, at least 
in part, to the improvement in the hepatic microcir-
culation after reperfusion .. 
Second, NO could exert hepatoprotective effects 
by inhibiting PMN adherence to the endothelium. 
PMNs, when adhered to endothelial cells and acti-
vated, have been demonstrated to aggravate liver 
damage by releasing myeloperoxidase, elastase, and 
proteolytic enzymes.40 NO itself inhibits PMN ad-
hesion in vitro.41 Lefer and colleagues42 also demon-
strated that an NO donor, SPM5185, lessened PMN 
adhesion to the endothelium in a canine heart 
model, which is consistent with our observation that 
the treatments significantly reduced the number of 
PMNs in postischemic liver tissues. Because 
L-NAME, a NOS antagonist, inhibits NO produc-
tion and up-regulates both P-selectin on the endo-
thelium and integrins on PMNs, the reduced num-
bers of infiltrated PMNs in the treated groups in this 
study might have resulted from down-regulation of 
. the expression of adhesion molecules by augmented 
NO.21.22 
The third possible explanation for the alleviating 
effects of NO on liver ischemia and reperfusion in-
jury relates to its superoxide scavenging property. Su-
peroxide radicals are implicated as an initial and po-
tential mediator of ischemia and reperfusion injury.2s 
Although it is also known that NO can combine with 
superoxide radicals to form the more highly toxic free 
radical species, peroxynitrite,43 peroxynitrite is un-
likely to be involved in our model because a very high 
level of peroxynitrite (ie, at least 500 J.tmoIlL) is re-
quired to produ~e cytotoxic effects.« In this study, 
the NO level was estimated to be 1 X 10-7 mollL 
according to the pharmacokinetics FK409, which is 
..5,000 times lower than the toxic level of peroxyni-
trIte. Most important, the presence of peroxynitrite 
has never been proved in an in vivo system. 
Finally, an alternative explanation for the benefi-
cial effects of the treatments might involve energy 
metabolism. The treatments maintained energy me-
tabolism at the end of ischemia and promoted its . 
restoration after reperfusion. NO modulates a key 
enzyme of the Krebs cycle (mitochondrial aconitase) 
and several mitochondrial electron transport cas-
cades.45.46 NO might act as an energy-sparing agent 
during ischemia. After reperfusion, the increase in 
HTBF by the treatments could contribute to the de-
livery of more nutrients and oxygen to the liver and 
improve the restoration of energy metabolism. Al-
though the precise mechanism is not fully under-
stood, favorable energy metabolism undoubtedly 
contributed to the better survival in the treated 
animals. 
In conclusion, we demonstrated the marked 
hepatoprotective effects of L-arginine and FK409 
against severe ischemia and reperfusion injury in ca-
nine livers. Both agents attenuated liver injury and 
rescued all animals from the critical insult. Although 
further studies are required to elucidate the exact 
mechanisms by which L-arginine and NO donors 
prevent ischemic liver injury, the supplementation of 
L-arginine, rather than FK409; appears to be a pos-
sible strategy in clinical settings because of its absence 
of adverse hypotensive effects. 
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